CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut™ Low Risk Trial. A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. In addition, contemporary data from the Evolut Low Risk Trial reinforces the robust long-term clinical outcomes of Evolut TAVR compared to SAVR in low-risk patients. The findings were presented as late-breaking clinical trials at the Cardiovascular Research Technologies (CRT) 2024 Conference.